The Lancet May 21, 2011

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Paul W Noble, Carlo Albera, Williamson Z Bradford et al.

Bottom Line

In two concurrent Phase III trials, pirfenidone significantly reduced the decline in lung function in one trial but did not reach statistical significance at week 72 in the other, though pooled and secondary analyses supported its efficacy in slowing IPF progression.

Key Findings

1. In Study 004, pirfenidone 2403 mg/day significantly reduced the decline in forced vital capacity (FVC) at week 72 compared with placebo (mean change -8.0% vs -12.4%; difference 4.4%, 95% CI 0.7 to 9.1; p=0.001).

2. In Study 004, fewer patients in the high-dose pirfenidone group had an FVC decline of at least 10% compared to placebo (20% vs 35%).

3. In Study 006, the difference in FVC change at week 72 was not statistically significant (mean change -9.0% vs -9.6%; difference 0.6%, p=0.501), although a consistent treatment effect was noted at earlier timepoints up to week 48 (p=0.005).

4. Across both studies, fewer overall deaths (6% vs 8%) and fewer IPF-related deaths (3% vs 7%) occurred in the high-dose pirfenidone groups compared to placebo.

5. Adverse events were more common with pirfenidone but rarely led to discontinuation; notable side effects included nausea (36% vs 17%), rash (32% vs 12%), and photosensitivity (12% vs 2%).

Study Design

Design

Randomized Controlled Trials

Double-Blind

Sample

779

Patients

Duration

72 wk

Median

Setting

Multinational

Population Patients aged 40-80 years with mild-to-moderate idiopathic pulmonary fibrosis (IPF)

Intervention Oral pirfenidone 2403 mg/day (evaluated in both trials); Study 004 additionally included a 1197 mg/day dose group

Comparator Matched oral placebo

Outcome Change in percentage predicted forced vital capacity (FVC) at week 72

Study Limitations

• Discordant primary endpoint results at week 72 between the two concurrent trials, as Study 006 failed to meet its primary efficacy endpoint.

• Distinct drug-related side effects (e.g., photosensitivity, rash, prominent gastrointestinal symptoms) could have led to partial unblinding of patients and investigators.

• The trials strictly enrolled patients with mild-to-moderate IPF, limiting generalizability to patients with severe disease or non-IPF interstitial lung diseases.

• Disease progression and mortality inherent to IPF led to missing data, requiring statistical imputation for final analysis.

Clinical Significance

The CAPACITY program provided landmark evidence that pirfenidone, a novel antifibrotic agent, could safely slow disease progression and lung function decline in IPF. Despite the mixed week 72 primary outcomes, the data demonstrated a favorable benefit-risk profile, establishing a new therapeutic paradigm and leading to regulatory approvals globally.

Historical Context

Prior to the development of pirfenidone, idiopathic pulmonary fibrosis was a fatal disease with no FDA-approved, disease-modifying therapies; the standard of care heavily relied on unproven immunosuppressants (like prednisone and azathioprine). Following promising Phase 2 results in Japan, the CAPACITY program evaluated pirfenidone on a global scale. Because of the discordant primary endpoints between the two CAPACITY trials at week 72, the US FDA requested an additional confirmatory trial (ASCEND, published in 2014) before finally granting approval, making pirfenidone one of the first successful targeted antifibrotic therapies for IPF.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the presumed mechanism of action of pirfenidone relate to the underlying pathophysiology of idiopathic pulmonary fibrosis (IPF), and what pulmonary function test (PFT) parameter was used as the primary endpoint to measure this in the CAPACITY trials?

Key Response

Pirfenidone exhibits anti-fibrotic and anti-inflammatory properties, primarily by downregulating pro-fibrotic cytokines like TGF-beta and inhibiting collagen synthesis. Forced Vital Capacity (FVC) is the standard PFT parameter used to monitor restrictive lung diseases like IPF, as it reliably reflects the progressive loss of lung volume due to fibrosis.

Resident

Given the clinical data from the CAPACITY trials, what are the most common adverse effects of pirfenidone that you must counsel a patient about before initiating therapy, and what baseline and ongoing laboratory monitoring is required?

Key Response

Residents need to manage drug tolerability safely. Pirfenidone is associated with significant gastrointestinal side effects (nausea, dyspepsia, anorexia) and a notable photosensitivity rash. Liver function tests (LFTs) must be checked at baseline and monitored monthly for the first 6 months due to the risk of drug-induced hepatotoxicity.

Fellow

The CAPACITY trials yielded discordant primary endpoint results at week 72, with 004 being significant and 006 not reaching significance. How do pulmonologists interpret this discordance in parallel Phase III trials, and how did the subsequent ASCEND trial address the methodological gaps to confirm pirfenidone's efficacy?

Key Response

Fellows must contextualize complex literature. The discordance in 006 was partly attributed to unexpected stability in the placebo group's decline at week 72. The ASCEND trial was subsequently designed to enrich the study population for patients with more predictable disease progression, ultimately confirming the FVC benefit and solidifying the drug's indication.

Attending

When initiating a newly diagnosed IPF patient on pirfenidone based on the CAPACITY and ASCEND data, how do you frame clinical expectations regarding disease reversal, symptom improvement, and lung function trajectories to ensure long-term adherence?

Key Response

Attendings must manage patient expectations effectively. It is critical to communicate that pirfenidone does not cure or reverse IPF, nor does it typically improve breathlessness; rather, its primary benefit is slowing the rate of FVC decline. Clear communication prevents patient frustration and improves adherence despite burdensome side effects.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

CAPACITY 004 and 006 utilized a rank ANCOVA model to analyze the change in percent predicted FVC. What are the statistical advantages and vulnerabilities of using rank-based nonparametric approaches for continuous primary endpoints in trials characterized by high anticipated dropout rates due to mortality?

Key Response

IPF trials face severe missing data challenges due to disease progression and death. A rank ANCOVA can handle non-normal distributions and allows researchers to assign the worst possible rank to patients who die, preserving the intention-to-treat principle. However, it can complicate the clinical interpretation of the effect size compared to standard mean difference analyses.

Journal Editor

When reviewing a single manuscript reporting two concurrent trials where one trial fails its primary endpoint at the designated time horizon, what editorial safeguards must be enforced to ensure that pooled analyses or secondary endpoints do not artificially obscure the negative primary outcome?

Key Response

Editors must actively prevent 'spin' in scientific literature. Highlighting pooled data or earlier time points (e.g., week 48 in CAPACITY 006) as evidence of efficacy requires strict adherence to pre-specified hierarchical analysis plans and transparent reporting, preventing post-hoc justification of a statistically failed trial component.

Guideline Committee

How do the findings of the CAPACITY trials, combined with subsequent supportive data, influence the ATS/ERS/JRS/ALAT clinical practice guidelines for IPF, particularly regarding the strength of recommendation for anti-fibrotics versus historical immunomodulatory therapies?

Key Response

The CAPACITY trials initiated a paradigm shift in IPF management. They provided the foundational evidence that led the ATS/ERS/JRS/ALAT guidelines to issue a conditional recommendation FOR the use of pirfenidone (and later nintedanib), while strongly recommending AGAINST older, harmful regimens like prednisone, azathioprine, and N-acetylcysteine (based on the PANTHER-IPF trial).

Clinical Landscape

Noteworthy Related Trials

2012

PANTHER-IPF Trial

n = 155 · NEJM

Tested

Triple therapy (prednisone, azathioprine, N-acetylcysteine)

Population

Patients with mild-to-moderate idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Change in forced vital capacity (FVC)

Key result: The triple-therapy arm was terminated early due to increased risks of mortality, hospitalizations, and serious adverse events compared to placebo.

2014

ASCEND Trial

n = 555 · NEJM

Tested

Pirfenidone 2403 mg/day

Population

Patients with idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Change in forced vital capacity (FVC) at 52 weeks

Key result: Pirfenidone significantly reduced the proportion of patients with a meaningful decline in FVC and improved progression-free survival.

2014

INPULSIS Trials

n = 1061 · NEJM

Tested

Nintedanib 150 mg twice daily

Population

Patients with idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Annual rate of decline in forced vital capacity (FVC)

Key result: Nintedanib significantly slowed disease progression by reducing the annual rate of FVC decline compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis